Literature DB >> 16222784

Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.

Christoffer W Tornøe1, Henrik Agersø, Henrik A Nielsen, Henrik Madsen, E Niclas Jonsson.   

Abstract

In this paper, the two non-linear mixed-effects programs NONMEM and NLME were compared for their use in population pharmacokinetic/pharmacodynamic (PK/PD) modelling. We have described the first-order conditional estimation (FOCE) method as implemented in NONMEM and the alternating algorithm in NLME proposed by Lindstrom and Bates. The two programs were tested using clinical PK/PD data of a new gonadotropin-releasing hormone (GnRH) antagonist degarelix currently being developed for prostate cancer treatment. The pharmacokinetics of intravenous administered degarelix was analysed using a three compartment model while the pharmacodynamics was analysed using a turnover model with a pool compartment. The results indicated that the two algorithms produce consistent parameter estimates. The bias and precision of the two algorithms were further investigated using a parametric bootstrap procedure which showed that NONMEM produced more accurate results than NLME together with the nlmeODE package for this specific study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16222784     DOI: 10.1007/s10928-005-5911-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  25 in total

1.  Population modelling in drug development.

Authors:  L Sheiner; J Wakefield
Journal:  Stat Methods Med Res       Date:  1999-09       Impact factor: 3.021

2.  Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.

Authors:  A Sharma; W F Ebling; W J Jusko
Journal:  J Pharm Sci       Date:  1998-12       Impact factor: 3.534

3.  Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Eur J Clin Pharmacol       Date:  2002-11-15       Impact factor: 2.953

4.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

5.  Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients.

Authors:  P Maire; X Barbaut; P Girard; A Mallet; R W Jelliffe; T Berod
Journal:  Int J Biomed Comput       Date:  1994-06

6.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography.

Authors:  L Yuh; S Beal; M Davidian; F Harrison; A Hester; K Kowalski; E Vonesh; R Wolfinger
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

Review 7.  Estimating population kinetics.

Authors:  S L Beal; L B Sheiner
Journal:  Crit Rev Biomed Eng       Date:  1982

Review 8.  Development of GnRH antagonists for prostate cancer: new approaches to treatment.

Authors:  T Cook; W P Sheridan
Journal:  Oncologist       Date:  2000

9.  The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.

Authors:  Henrik Agersø; Wolfgang Koechling; Magnus Knutsson; Rolf Hjortkjaer; Mats O Karlsson
Journal:  Eur J Pharm Sci       Date:  2003-11       Impact factor: 4.384

10.  Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix.

Authors:  Christoffer W Tornøe; Henrik Agersø; Henrik A Nielsen; Henrik Madsen; E Niclas Jonsson
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

View more
  5 in total

Review 1.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 2.  Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

3.  Semiparametric mixed-effects analysis of PK/PD models using differential equations.

Authors:  Yi Wang; Kent M Eskridge; Shunpu Zhang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-09-10       Impact factor: 2.745

4.  Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blocker.

Authors:  Pravin R Jadhav; Henrik Agersø; Christoffer W Tornøe; Jogarao V S Gobburu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-08-08       Impact factor: 2.745

5.  Degarelix.

Authors:  James E Frampton; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.